Minerva Surgical

Executive Summary

Minerva Surgical is a medical device company specializing in minimally invasive intrauterine devices for treating Abnormal Uterine Bleeding (AUB). Its product portfolio includes endometrial ablation systems, hysteroscopic resectors, and diagnostic hysteroscopy tools. In January 2026, Minerva's business assets were acquired by Axora Medical, positioning the combined entity to strengthen its footprint in women's uterine health. The acquisition brings together complementary technologies and expands Axora's commercial reach. While Minerva operates as part of Axora post-acquisition, its technology remains central to addressing the root causes of AUB, a condition affecting millions of women globally. The company targets the underserved market for conservative, uterine-preserving treatments, offering a single-use, disposable device ecosystem that reduces infection risk and improves clinical efficiency. Under new ownership, Minerva aims to accelerate adoption through a larger sales force and expanded regulatory approvals. However, the lack of public financial data and early-stage integration risks temper near-term visibility.

Upcoming Catalysts (preview)

• Q3 2026Integration of Minerva's product line into Axora Medical's commercial platform80% success
• TBDFDA clearance for next-generation endometrial ablation device60% success
• Q4 2026Expansion into European markets through CE marking under Axora70% success